Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BCD-217

Phase 3Biologic

BCD-217 is one of 66 biologic programs targeting Metastatic Melanoma. It is currently in Phase 3.

2

Indications

3

Total Trials

2

Active Trials

65

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

MelanomaActive, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Opdivo

Bristol-Myers Squibb

Roferon-a

ABI-007

Bristol-Myers Squibb

GSK2118436

Investigator's Choice

Zelboraf

CConrado Roberto Hoffmann Filho

BCD-217

Intron a

Opdualag

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Melanoma

NCT05751928

Clinical

Trials by Indication[1]

Metastatic Melanoma2 trials

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Unknown status·BBiocad·Phase 2·NCT03913923·117 enrolled

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting·BBiocad·Phase 3·NCT05732805·270 enrolled

Melanoma1 trial

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Active, not recruiting·BBiocad·Phase 3·NCT05751928·411 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BCD-217. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCD-217 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCD-217. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: BBiocad

Related News